- Home
- CEP vs LPTX Comparison
CEP vs LPTX Comparison
Compare CEP & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEP
- LPTX
- Stock Information
- Founded
- CEP 2020
- LPTX 2011
- Country
- CEP United States
- LPTX United States
- Employees
- CEP N/A
- LPTX N/A
- Industry
- CEP
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEP
- LPTX Health Care
- Exchange
- CEP NYSE
- LPTX Nasdaq
- Market Cap
- CEP 133.8M
- LPTX 119.6M
- IPO Year
- CEP 2024
- LPTX N/A
- Fundamental
- Price
- CEP $10.38
- LPTX $0.48
- Analyst Decision
- CEP
- LPTX Buy
- Analyst Count
- CEP 0
- LPTX 3
- Target Price
- CEP N/A
- LPTX $8.50
- AVG Volume (30 Days)
- CEP 3.2K
- LPTX 1.5M
- Earning Date
- CEP 01-01-0001
- LPTX 03-17-2025
- Dividend Yield
- CEP N/A
- LPTX N/A
- EPS Growth
- CEP N/A
- LPTX N/A
- EPS
- CEP 0.06
- LPTX N/A
- Revenue
- CEP N/A
- LPTX N/A
- Revenue This Year
- CEP N/A
- LPTX N/A
- Revenue Next Year
- CEP N/A
- LPTX N/A
- P/E Ratio
- CEP $187.78
- LPTX N/A
- Revenue Growth
- CEP N/A
- LPTX N/A
- 52 Week Low
- CEP $9.99
- LPTX $0.47
- 52 Week High
- CEP $10.95
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- CEP N/A
- LPTX 19.00
- Support Level
- CEP N/A
- LPTX $0.47
- Resistance Level
- CEP N/A
- LPTX $0.53
- Average True Range (ATR)
- CEP 0.00
- LPTX 0.04
- MACD
- CEP 0.00
- LPTX 0.07
- Stochastic Oscillator
- CEP 0.00
- LPTX 7.42
About CEP CANTOR EQUITY PARTNERS INC
Cantor Equity Partners Inc is a blank check company.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .